A phase 1 trial of E7974 administered on day 1 of a 21‐day cycle in patients with advanced solid tumors

BACKGROUND: E7974, a synthetic analog of hemiasterlin, interacts with the tubulin molecule and overcomes resistance to other antitubulin drugs (taxanes and vinca alkaloids). METHODS: In a phase 1 study, E7974 was given intravenously over a 2‐ to 5‐minute infusion on day 1 of every 21‐day cycle. Adul...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2012-09, Vol.118 (17), p.4262-4270
Main Authors: Rocha‐Lima, Caio M., Bayraktar, Soley, MacIntyre, Jessica, Raez, Luis, Flores, Aurea M., Ferrell, Annapoorna, Rubin, Eric H., Poplin, Elizabeth A., Tan, Antoinette R., Lucarelli, Antonio, Zojwalla, Naseem
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antimitotic Agents - adverse effects
Antimitotic Agents - therapeutic use
antitubulin resistance
Biological and medical sciences
Disease-Free Survival
Drug Administration Schedule
E7974
Female
hemiasterlin
Humans
Male
maximal tolerated dose
Maximum Tolerated Dose
Medical sciences
Middle Aged
Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
Neoplasms - drug therapy
Neoplasms - pathology
Oligopeptides - adverse effects
Oligopeptides - pharmacokinetics
Oligopeptides - therapeutic use
Piperidines - adverse effects
Piperidines - pharmacokinetics
Piperidines - therapeutic use
refractory solid tumors
toxicity profile
Treatment Outcome
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND: E7974, a synthetic analog of hemiasterlin, interacts with the tubulin molecule and overcomes resistance to other antitubulin drugs (taxanes and vinca alkaloids). METHODS: In a phase 1 study, E7974 was given intravenously over a 2‐ to 5‐minute infusion on day 1 of every 21‐day cycle. Adult patients with advanced refractory solid tumors who had adequate organ function and Eastern Cooperative Oncology Group performance status 0 to 2 were eligible for this study. A modified Fibonacci schema was used. The maximal tolerated dose (MTD) was the dose where
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.27428